Clinical Trial Update: Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on polaprezinc for castration-resistant prostate cancer resistant to enzalutamide or abiraterone, covering Phase 1 and Phase 2 results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Polaprezinc (Zinc L-carnosine)

Snippet

Sponsor: Jiangnan University | Conditions: Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED